Journal
CANCER MEDICINE
Volume 8, Issue 3, Pages 1054-1065Publisher
WILEY
DOI: 10.1002/cam4.1998
Keywords
hepatocellular carcinoma; liver cirrhosis; liver diseases; meta-analysis; risk of HCC
Categories
Funding
- Kanagawa Association of Medical and Dental Practitioners
Ask authors/readers for more resources
Background It is well known that the incidence of developing hepatocelluler carcinoma (HCC) is increased in liver cirrhosis of different etiologies. However, comparison of HCC incidence in various liver diseases has not yet been estimated. We surveyed this comparison. Methods The PubMed database was examined (1989-2017) for studies published in English language regarding the prospective follow-up results for the development of HCC in various liver diseases. A meta-analysis was performed for each liver disease. Results The annual incidence (%) of HCC in the non-cirrhotic stage and cirrhotic stage, and the ratio of HCC incidence in the cirrhotic stage/non-cirrhotic stage were as follows. (a) hepatitis B virus liver disease: 0.37%-> 3.23% (8.73-fold), (b) hepatitis C virus liver diseases: 0.68%-> 4.81% (7.07-fold), (c) primary biliary cholangitis (0.26%-> 1.79%, 6.88-fold), (d) autoimmune hepatitis (0.19%-> 0.53%, 2.79-fold), and (e) NASH (0.03%-> 1.35%, 45.00-fold). Regarding primary hemochromatosis and alcoholic liver diseases, only follow-up studies in the cirrhotic stage were presented, 1.20% and 2.06%, respectively. Conclusions When the liver diseases advance to cirrhosis, the incidence of HCC is markedly increased. The development of HCC must be closely monitored by ultrasonography, magnetic resonance imaging, and computed tomography, irrespective of the different kinds of liver diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available